research product . 2020

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

Fintelman-Rodrigues, Natalia et al.;
Open Access English
  • Published: 04 Apr 2020
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the ongoing pandemic of 2019 CoV disease (COVID-19), which is already responsible for far more deaths than were reported during the previous public health emergencies of international concern provoked by two related pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of any clinically approved drug that could be repurposed to combat COVID-19 would allow the rapid implementation of potentially life-saving procedures to complement social distancing and isolation protocols. The major protease (Mpro) of SARS-CoV-2 is considered a promising target for drug inte...
Persistent Identifiers
Subjects
Medical Subject Headings: virus diseasesviruses
free text keywords: COVID-19, SARS-CoV, Atazanavir Sulfate, Cytokines
Related Organizations
Communities
  • COVID-19
Download from
53 references, page 1 of 4

1. Masters, P. S. The molecular biology of coronaviruses. Adv. Virus Res. 66, 193-292 (2006). [OpenAIRE]

2. Cui, J., Li, F. & Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181-192 (2019).

3. Lam, T. T.-Y. et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature (2020) doi:10.1038/s41586-020-2169-0.

4. WHO | Middle East respiratory syndrome coronavirus (MERS-CoV). WHO http://www.who.int/emergencies/mers-cov/en/ (2020).

5. WHO | Severe Acute Respiratory Syndrome (SARS). WHO https://www.who.int/csr/sars/en/ (2020).

6. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 0, (2020).

7. Romer, P. & Garber, A. M. Opinion | Will Our Economy Die From Coronavirus? The New York Times (2020).

8. Harrison, C. Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. (2020) doi:10.1038/d41587-020-00003-1.

9. Organization, W. H. WHO R&D Blueprint: informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection, Geneva, Switzerland, 24 January 2020. (2020).

10. De Clercq, E. & Li, G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev 29, 695-747 (2016).

11. Wu, C.-Y. et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. U. S. A. 101, 10012-10017 (2004).

12. Fehr, A. R. & Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. Clifton NJ 1282, 1-23 (2015).

13. Gong, Y. et al. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. Expert Opin. Drug Metab. Toxicol. 15, 417-427 (2019).

14. Cao, B. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. (2020) doi:10.1056/NEJMoa2001282.

15. Stanley, T. L. et al. Effects of Switching from Lopinavir/ritonavir to Atazanavir/ritonavir on Muscle Glucose Uptake and Visceral Fat in HIV Infected Patients. AIDS Lond. Engl. 23, 1349-1357 (2009).

53 references, page 1 of 4
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the ongoing pandemic of 2019 CoV disease (COVID-19), which is already responsible for far more deaths than were reported during the previous public health emergencies of international concern provoked by two related pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of any clinically approved drug that could be repurposed to combat COVID-19 would allow the rapid implementation of potentially life-saving procedures to complement social distancing and isolation protocols. The major protease (Mpro) of SARS-CoV-2 is considered a promising target for drug inte...
Persistent Identifiers
Subjects
Medical Subject Headings: virus diseasesviruses
free text keywords: COVID-19, SARS-CoV, Atazanavir Sulfate, Cytokines
Related Organizations
Communities
  • COVID-19
Download from
53 references, page 1 of 4

1. Masters, P. S. The molecular biology of coronaviruses. Adv. Virus Res. 66, 193-292 (2006). [OpenAIRE]

2. Cui, J., Li, F. & Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181-192 (2019).

3. Lam, T. T.-Y. et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature (2020) doi:10.1038/s41586-020-2169-0.

4. WHO | Middle East respiratory syndrome coronavirus (MERS-CoV). WHO http://www.who.int/emergencies/mers-cov/en/ (2020).

5. WHO | Severe Acute Respiratory Syndrome (SARS). WHO https://www.who.int/csr/sars/en/ (2020).

6. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 0, (2020).

7. Romer, P. & Garber, A. M. Opinion | Will Our Economy Die From Coronavirus? The New York Times (2020).

8. Harrison, C. Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. (2020) doi:10.1038/d41587-020-00003-1.

9. Organization, W. H. WHO R&D Blueprint: informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection, Geneva, Switzerland, 24 January 2020. (2020).

10. De Clercq, E. & Li, G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev 29, 695-747 (2016).

11. Wu, C.-Y. et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. U. S. A. 101, 10012-10017 (2004).

12. Fehr, A. R. & Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. Clifton NJ 1282, 1-23 (2015).

13. Gong, Y. et al. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. Expert Opin. Drug Metab. Toxicol. 15, 417-427 (2019).

14. Cao, B. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. (2020) doi:10.1056/NEJMoa2001282.

15. Stanley, T. L. et al. Effects of Switching from Lopinavir/ritonavir to Atazanavir/ritonavir on Muscle Glucose Uptake and Visceral Fat in HIV Infected Patients. AIDS Lond. Engl. 23, 1349-1357 (2009).

53 references, page 1 of 4
Any information missing or wrong?Report an Issue